New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
06:22 EDTHZNP, ESRX, CVSHorizon Pharma said Duexis, Vimovo to be placed on CVS, Express exlclusion lists
Horizon Pharma (HZNP) said it has been verbally notified that in August, two pharmacy benefit managers, CVS Caremark (CVS) and Express Scripts (ESRX), expect to announce DUEXIS and VIMOVO will no longer be on their formularies and will be placed on their exclusion lists effective January 1, 2015. As a change in Caremark and ESI formulary status would not take effect until 2015, Horizon Pharma does not expect this potential action to impact the financial guidance of $270M-280M for net revenues and $80M-90M for adjusted EBITDA for fiscal 2014 as provided in first quarter earnings press release dated May 9. In response to potentially being placed on Caremarkís and ESIís exclusion lists, the company said it will immediately accelerate patient and physician focused commercial model to focus prescriptions through other channels such as our Prescriptions Made Easy program, continue working with many of the other PBMs and evaluate price increases. We estimate approximately 20%-30% of DUEXIS and VIMOVO prescriptions could be impacted by the potential actions by Caremark and ESI. In the future, if additional healthcare plans adopt the Caremark or ESI exclusion lists or otherwise exclude DUEXIS or VIMOVO from the formularies they use, which they are not required to do, there could possibly be additional DUEXIS and VIMOVO prescriptions affected.
News For HZNP;CVS;ESRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
16:37 EDTCVS, ESRXSpecialists On Call names Hammad Shah as CEO
Subscribe for More Information
11:45 EDTCVS, ESRXLeerink healthcare tech/pharma analysts hold analyst/industry conference call
Subscribe for More Information
March 17, 2015
08:04 EDTESRXExpress Scripts has a conference call hosted by JPMorgan
JPMorgan Analyst Gill will host a conference call with CEO George Paz on March 18 at 11 am.
06:31 EDTCVSStudies find Gilead's hepatitis C drugs cost effective, Reuters says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use